Identification of Anticancer Drugs Associated With Cancer Therapy‐Related Cardiac Dysfunction in Pediatrics—Analysis of the WHO Pharmacovigilance Database
Within VigiBase, we pinpointed 16 anticancer drugs significantly associated with CTRCD reporting in pediatrics. Our research validated several associations already thoroughly reported in children (such as with anthracyclines), and unveiled novel signals for systemic exposure to topotecan and dactinomycin. The relevance of these findings, especially considering the frequency of co-administration of agents and the lack of information regarding radiation exposure and chemotherapy dosage, would need to be evaluated in the context of clinical trials that use or have used these agents.
Authors
- Basile Chrétien (ORCID: https://orcid.org/0000-0002-7483-2489)
- Joachim Alexandre
- Jérémie Rouger (ORCID: https://orcid.org/0000-0001-6448-8832)
- Damien Legallois (ORCID: https://orcid.org/0000-0002-2297-4418)
- Fabien Labombarda (ORCID: https://orcid.org/0000-0003-4435-4401)
- Charles Dolladille (ORCID: https://orcid.org/0000-0003-0449-6261)
Institutions
- Inserm (FR)
- Normandie Université (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2025-04-20
- DOI
- https://doi.org/10.1002/pbc.31727
- Citations
- 2
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- World Health Organization